Effect of rosiglitazone on hepatic LRP1

Moon et al. hypothesised that thiazolidinediones may increase hepatic LRP1 and the hepatic clearance of remnant lipoproteins. They conducted a study to investigate the effect of rosiglitazone on the expression and function of hepatic LRP1. HepG2 cells were incubated with various concentrations of rosiglitazone. Male Long-Evans Tokushima Otsuka rats and Otsuka-Long-Evans-Tokushima Fatty rats were treated with rosiglitazone for five weeks. The expression and function of LRP1 in HepG2 cells and liver samples of rats were analysed. They found that a diabetic condition including a high glucose condition decreased the expression of hepatic LRP1. In addition, rosiglitazone treatment increased LRP1 expression and function in HepG2 cells and in the livers of diabetic rats. These data also suggest that decreased hepatic LRP1 in a diabetic condition is associated with the development of atherogenic dyslipidemia and that increased hepatic LRP1 by thiazolidinediones could contribute to an improvement in atherogenic lipid profiles in diabetic patients. Moon et al. (2012) Journal of Molecular Endocrinology 49 165-174.

Read the full article at: DOI: 10.1530/JME-12-0119